GSK readies 'bubble boy' drug as big pharma bets on gene therapy

GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight adenosine deaminase severe combined immune deficiency (ADA-SCID) in the latest sign of a renaissance in the technology to fix faulty genes.